oncostatin-M

Oncostatin-M (OSM) is a pleiotropic cytokine belonging to the interleukin-6 (IL-6) family. It is primarily produced by activated T cells, monocytes, macrophages, and dendritic cells. OSM signals through two types of receptor complexes: the type I receptor (consisting of gp130 and leukemia inhibitory factor receptor [LIFR]) and the type II receptor (consisting of gp130 and oncostatin M receptor beta [OSMRβ]). This binding activates downstream signaling pathways, including the JAK/STAT (primarily STAT3), MAPK, and PI3K/AKT pathways, which regulate cell proliferation, differentiation, hematopoiesis, and inflammatory responses. Recombinant human oncostatin-M was historically developed as a therapeutic candidate by Bristol-Myers Squibb under the development codes BMS-196854 and BMS-196843 for potential anti-inflammatory, thrombocytopoietic, and antineoplastic indications. However, its clinical development was discontinued. Today, oncostatin-M is widely utilized as a research-use-only (RUO) reagent in stem cell differentiation and laboratory assays, while the OSM signaling pathway remains a major therapeutic target for monoclonal antibodies and small-molecule inhibitors in inflammatory bowel disease, rheumatoid arthritis, and cancer.

Other names

OSMOncostatin MOncostatin-Mrecombinant human oncostatin M